Related Research Articles
Immunosuppressive drugs, also known as immunosuppressive agents, immunosuppressants and antirejection medications, are drugs that inhibit or prevent the activity of the immune system.
Matuzumab is a humanized monoclonal antibody for the treatment of cancer. It binds to the epidermal growth factor receptor (EGFR) with high affinity. The mouse monoclonal antibody (mAb425) from which matuzumab was developed at the Wistar Institute in Philadelphia, Pennsylvania
Nimotuzumab is a humanized monoclonal antibody that as of 2014 had orphan status in the US and EU for glioma, and marketing approval in India, China, and other countries for squamous cell carcinomas of the head and neck, and was undergoing several clinical trials.
Tanezumab is a monoclonal antibody against nerve growth factor as a treatment for pain via a novel mechanisms different from conventional pain-killer drugs. Tanezumab was discovered and developed by Rinat Neuroscience and was acquired by Pfizer in 2006.
Figitumumab is a monoclonal antibody targeting the insulin-like growth factor-1 receptor that was investigated for the treatment of various types of cancer, for example adrenocortical carcinoma and non-small cell lung cancer (NSCLC).
Siltuximab is a chimeric monoclonal antibody. It binds to interleukin-6. Siltuximab has been investigated for the treatment of neoplastic diseases: metastatic renal cell cancer, prostate cancer, other types of cancer, and for Castleman's disease.
A microantibody is an artificial short chain of amino acids copied from a fully functional natural antibody. Microantibodies can stop viruses such as HIV from infecting cells in vitro.
Dalotuzumab is an anti-IGF1 receptor (IGF1R) humanized monoclonal antibody designed for the potential treatment of various cancers. Common adverse effects include hyperglycemia, nausea, vomiting, and fatigue. Dalotuzumab was developed by Merck and Co., Inc.
Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers.
Mavrilimumab is a human monoclonal antibody that inhibits human granulocyte macrophage colony-stimulating factor receptor (GM-CSF-R).
Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2. As of May 2017, it is in Phase II clinical trials for the treatment of diabetic macular edema.
Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It binds to KIR2DL1/2L3.
Rinat Neuroscience Corporation was a privately held biotechnology company that discovered and developed antibody-based drugs, including:
Rinucumab (REGN2176) is a monoclonal antibody designed for the treatment of neovascular age-related macular degeneration.
Pamrevlumab is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer. It binds to the connective tissue growth factor (CTGF) protein.
Flotetuzumab is a bispecific antibody designed for the treatment of acute myeloid leukemia.
Nerve growth factor (NGF) inhibitors are a class of compounds that inhibit the action of the neurotrophin nerve growth factor by targeting NGF molecules or NGF receptors. NGF inhibitors have demonstrated therapeutic potential in treatment of certain chronic pain disorders, including osteoarthritis, and chronic lower back pain. Two NGF inhibitors are undergoing clinical trials as potential treatments for pain disorders.
Frunevetmab, sold under the brand name Solensia, is a medication used to treat pain associated with osteoarthritis in cats.
Bedinvetmab, sold under the brand name Librela is a canine monoclonal antibody used for the control of pain associated with osteoarthritis in dogs. Librela is sponsored by Zoetis.
References
- ↑ "Fasinumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
- ↑ Tiseo PJ, Ren H, Mellis S (2014). "Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study". Journal of Pain Research. 7: 523–530. doi: 10.2147/JPR.S65974 . PMC 4155988 . PMID 25210473.
- ↑ Oo WM, Hunter DJ (November 2021). "Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review". BioDrugs. 35 (6): 611–641. doi:10.1007/s40259-021-00504-8. PMID 34807432. S2CID 244509341.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |